Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors (PET/Ga68) Phase-II, prospective, open label, no control group to assess the safety of 68Ga-DOTA-TATE [...]
“Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” – a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and [...]
After review of the results of our recently conducted patient support survey and based on input from our local communities and our local Support Group Leaders, we are implementing the [...]
Over the last several years CNETS Canada has worked hard to continuously improve our website and the information contained in it to ensure that it is highly functional and as [...]
A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors Not yet [...]